- Report
- December 2023
- 150 Pages
Global
From €5717EUR$5,950USD£4,908GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- January 2024
- 150 Pages
Global
From €4660EUR$4,850USD£4,000GBP
- Report
- November 2023
- 149 Pages
Global
From €2401EUR$2,499USD£2,061GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Report
- November 2023
- 126 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Report
- July 2018
- 115 Pages
Global
From €1321EUR$1,375USD£1,134GBP
€2642EUR$2,750USD£2,268GBP
- Report
- August 2022
- 120 Pages
Global
From €4324EUR$4,500USD£3,712GBP
- Drug Pipelines
- November 2020
- 93 Pages
Global
From €1922EUR$2,000USD£1,650GBP
- Report
- January 2021
- 146 Pages
China, Global
From €3000EUR$3,345USD£2,665GBP
- Report
- July 2022
- 64 Pages
Global
From €1922EUR$2,000USD£1,650GBP
Ondansetron is a medication used to treat nausea and vomiting caused by cancer treatments, such as chemotherapy and radiation therapy. It is also used to prevent nausea and vomiting after surgery. Ondansetron is a serotonin 5-HT3 receptor antagonist, which works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. It is available in both oral and intravenous forms.
Ondansetron is a widely used medication in the gastrointestinal drugs market. It is used to treat nausea and vomiting caused by a variety of conditions, including chemotherapy, radiation therapy, and post-operative nausea and vomiting. It is also used to prevent nausea and vomiting in patients undergoing chemotherapy or radiation therapy.
The market for gastrointestinal drugs is highly competitive, with many companies offering a variety of products. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Pfizer, Sanofi, and Novartis. Other companies in the market include AstraZeneca, Takeda Pharmaceuticals, and Daiichi Sankyo. Show Less Read more